이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

VITA 34 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Jakub Baran

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	2.3yrs
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	4yrs

최근 관리 업데이트

Recent updates

CEO

Jakub Baran

2.3yrs

테뉴어

Mr. Jakub Julian Baran serves as Chairman of the Management Board and Chief Executive Officer at VITA 34 AG since March 22, 2022. He serves as Member of the Supervisory Board at Betacom S.A. since May 2019...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Isadore Ances	Member of Scientific & Medical Advisory Board	no data	데이터 없음	데이터 없음
A. Bader	Member of Scientific & Medical Advisory Board	no data	데이터 없음	데이터 없음
Robert Iannone	Member of Scientific & Medical Advisory Board	no data	데이터 없음	데이터 없음
W. Holzgreve	Member of Scientific & Medical Advisory Board	no data	데이터 없음	데이터 없음
Carlo Croce	Member of Scientific & Medical Advisory Board	no data	데이터 없음	데이터 없음
Jack Goldberg	Member of Scientific & Medical Advisory Board	no data	데이터 없음	데이터 없음
E. Wunder	Member of Scientific & Medical Advisory Board	no data	데이터 없음	데이터 없음
Ronald Wapner	Member of Scientific & Medical Advisory Board	no data	데이터 없음	데이터 없음
Zbigniew Mrowiec	Member of Scientific & Medical Advisory Board	no data	데이터 없음	데이터 없음
Florian Schuhbauer	Deputy Chairman of the Supervisory Board	4yrs	€20.00k	데이터 없음
Alexander Granderath	Chairman of Supervisory Board	2.6yrs	데이터 없음	데이터 없음
Frank Kohler	Independent Member of the Supervisory Board	7.1yrs	€30.00k	데이터 없음

4.0yrs

평균 재임 기간

경험이 풍부한 이사회: V3V 의 이사회는 경험(평균 재직 기간 3.9 년)으로 간주됩니다.

VITA 34 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

VITA 34 AG, Annual General Meeting, Jun 29, 2022

VITA 34 AG, Annual General Meeting, Jun 30, 2021

Recent updates

First quarter 2024 earnings released: €0.05 loss per share (vs €0.18 loss in 1Q 2023)

New major risk - Revenue and earnings growth

Price target increased by 15% to €6.00

No longer forecast to breakeven

VITA 34 AG to Report Q1, 2024 Results on May 31, 2024

New minor risk - Share price stability

New minor risk - Profitability

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: €0.10 loss per share (vs €0.02 loss in 3Q 2022)

Second quarter 2023 earnings released: €0.07 loss per share (vs €0.30 loss in 2Q 2022)

New minor risk - Share price stability

New minor risk - Market cap size

First quarter 2023 earnings released: €0.18 loss per share (vs €0.18 loss in 1Q 2022)

Vita 34 Ag Starts Recruitment for Clinical Trial with Car-T Drug Candidate

Full year 2022 earnings released: €1.71 loss per share (vs €0.63 loss in FY 2021)

VITA 34 AG to Report Q3, 2023 Results on Nov 21, 2023

Third quarter 2022 earnings released: €0.02 loss per share (vs €0.11 profit in 3Q 2021)

Price target decreased to €10.50

Second quarter 2022 earnings released: EPS: €0.30 (vs €0.002 loss in 2Q 2021)

VITA 34 AG Revises Earnings Guidance for the Financial Year 2022

VITA 34 AG to Report Q2, 2022 Results on Aug 30, 2022

VITA 34 AG, Annual General Meeting, Jun 29, 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

VITA 34 AG to Report Q1, 2022 Results on May 31, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Vita 34 Ag Provides Revenue Guidance for the Financial Year 2022

Price target increased to €25.00

Price target increased to €21.10

Third quarter 2021 earnings released: EPS €0.14 (vs €0.18 in 3Q 2020)

Second quarter 2021 earnings released

VITA 34 AG (XTRA:V3V) entered into a Business Combination Agreement to acquire Polski Bank Komórek Macierzystych S.A. (WSE:BKM) (PKBM) from AOC Health GmbH, Jakub Baran, Tomasz Baran and others for approximately PLN 840 million.

VITA 34 AG Provides Earnings Guidance for the Year 2021

First quarter 2021 earnings released

Full year 2020 earnings released: EPS €0.37 (vs €0.18 in FY 2019)

VITA 34 AG to Report Q1, 2021 Results on May 11, 2021

New 90-day high: €14.05

New 90-day high: €13.00

VITA 34 AG, Annual General Meeting, Jun 30, 2021

Price target raised to €17.50

Third quarter 2020 earnings released: EPS €0.18

Revenue and earnings miss expectations

New 90-day low: €11.15

Earnings released

VITA 34 AG to Report Q2, 2020 Results on Aug 27, 2020

New 90-day low - €11.60

AOC Health GmbH acquired a 27.3% stake in VITA 34 AG (XTRA:V3V).

CEO

테뉴어

이사회 구성원

평균 재임 기간